News

Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Lilly requests EMA to re-examine Alzheimer's drug recommendation
Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...
24/7 Wall St.8h
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly Files Slew of Lawsuits Over Zepbound and Mounjaro
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...